Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Behr, Thomas M ^a   Salib, Alexandra L ^a   Liersch, Torsten ^a   Béhé, Martin ^a   Angerstein, Christa ^a   Blumenthal, Rosalyn D ^b   Fayyazi, Afshin ^a   Sharkey, Robert M ^b   Ringe, Bernhard ^a   Becker, Heinz ^a   Wörmann, Bernhard ^a   Hiddemann, Wolfgang ^a   Goldenberg, David M ^b   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; FLUOROURACIL; FOLINIC ACID; IODINE 131; IRINOTECAN; MONOCLONAL ANTIBODY F 023C5; MONOCLONAL ANTIBODY MN 14; UNCLASSIFIED DRUG;

ANIMAL MODEL; BONE MARROW TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REMISSION;

ADULT; AGED; ANIMALS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; RADIOIMMUNOTHERAPY;

EID: 0032741274     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. DeVita, V. T., Hellman, S., and Rosenberg, S. A. (eds.). Cancer: Principles and Practice of Oncology (Ed. 5). Philadelphia: Lippincott-Raven, 1997.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., and Glick, J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352-358, 1990.
3. Stangl, R., Altendorf-Hofmann, A., Charnley, R. M., and Scheele, J. Factors influencing the natural history of colorectal liver metastases. Lancet, 343: 1405-1410, 1994.
4. Machover, D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer (Phila.), 80: 1179-1187, 1997.
5. Pitot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Mailliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., Levitt, R., and Windschitl, H. E. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 15: 2910-2919, 1997.
6. Rothenberg, M. L., Cox, J. V., DeVore, R. F., Hainsworth, J. D., Pazdur, R., Rivkin, S. E., Macdonald, J. S., Geyer, C. E., Jr., Sandbach, J., Wolf, D. L., Mohrland, J. S., Elfring, G. L., Miller, L. L, and Von Hoff, D. D. A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (Phila.), 85: 786-795, 1999.
7. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höfken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., and Witte J. The German cancer Aid 17-1A Study Group: randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
8. Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
9. Göttlinger, H. G., Funke, I., Johnson, J. P., Gokel, J. M., and Riethmüller, G. The epithelial surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer., 38: 47-53, 1986.
10. Saleh, M. N., Lobuglio, A. F., Wheeler, R. H., Rogers, K. J., Haynes, A., Lee, J. Y., and Khazaeli, M. B. A Phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol. Immunother., 32: 185-190, 1990.
11. Behr, T. M., Goldenberg, D. M., and Becker, W. S. Radioimmunotherapy of solid tumors: a review "Of Mice and Men." Hybridoma, 16: 101-107, 1997.
12. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
13. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet, 346: 336-340, 1995.
14. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Siegel, J. A., and Goldenberg, D. M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J. Nucl. Med., 38: 409-418, 1997.
15. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res., 50: 1039-1042, 1990.
16. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J. Nucl. Med., 36: 430-441, 1995.
17. Hansen, H. J., Goldenberg, D. M., Newman, E. S., Grebenau, R., and Sharkey, R. M. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer (Phila.), 71: 3478-3485, 1993.
18. Sharkey, R. M., Goldenberg, D. M., Murthy, S., Pinsky, H., Vagg, R., Pawlyk, D., Siegel, J. A., Wong, G. Y., Gascon, P., Izon, D. O., and Hansen, H. J. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer (Phila.), 71: 2082-2096, 1993.
19. Primus, F. J., Newell, K. D., Blue, A., and Goldenberg, D. M. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res., 43: 686-692, 1983.
20. Sharkey, R. M., Juweid, M., Shevitz, J., Behr, T., Dunn, R., Swayne, L. C., Wong, G. Y., Blumenthal, R. D., Griffiths, G. L., Siegel, J. A., and Goldenberg, D. M. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res., 55: 5935-5945, 1995.
21. 131I-labeled CO17-1A in a human colorectal cancer model. Int. J. Cancer., 76: 738-748, 1998.
22. Goldenberg, D. M., Witte, S., and Elster, K. GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation, 4: 760-764, 1966.
23. Blumenthal, R. D., Sharkey, R. M., Natale, A. M., Kashi, R., Wong, G., and Goldenberg, D. M. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res., 54: 142-151, 1994.
24. 90Y-Dosimetry in the nude mouse: evaluation of three dosimetry models in relation to the observed biological effects in the radioimmunotherapy of human colon cancer xenografts. Proceedings of the 6th International Radiopharm. Dosim. Symposium, Gatlinburg, TN, 1996.
25. Behr, T. M., Sharkey, R. M., Sgouros, G., Blumenthal, R. D., Dunn, R. M., Kolbert, K., Griffiths, G. L., Siegel, J. A., Becker, W. S., and Goldenberg, D. M. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (Phila.). 80: 2591-2610, 1997.
26. Seegenschmiedt, M. H. (ed.). Nebenwirkungen in der Onkologie: Internationale Systematik und Dokumentation. Berlin: Springer-Verlag, 1998.
27. Behr, T. M., Dunn, R. M., Gratz, S., Weber, E., Herrmann, A., and Becker, W. An automated scheme for internal radiation dosimetry in nuclear therapy: gamma- or bremsstrahlung-based dose calculation in the therapy of differentiated thyroid cancer, radiosynoviorthesis, bone pain palliation and radioimmuno-therapy. J. Nucl. Med., 38: 225P, 1997.
28. Stabin, M. G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 37: 538-546, 1996.
29. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Ying, Z., Zhang, C. H., Swayne, L. C., Vardi, Y., Siegel, J. A., and Goldenberg, D. M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med., 38: 858-870, 1997.
30. Vogel, C. A., Galmiche, M. C., Westermann P., Sun L. Q., Pelegrin, A., Folli, S., Bischof-Delaloye A., Slosman, D. O., Mach, J. P., and Buchegger, F. Carcinoembryonic antigen expression, antibody localization and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy. Int. J. Cancer, 67: 294-302, 1996.
31. Vogel, C. A., Galmiche, M. C., and Buchegger, F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res., 57: 447-453, 1997.
32. Brand, M. I., Casillas, S., Dietz, D. W., Milsom, J. W., and Vladisavljevic, A. Development of a reliable colorectal cancer liver metastasis model. J. Surg. Res., 63: 425-432, 1996.
33. Wagner, H. E., Thomas, P., Wolf, B. C., Zamcheck, N., Jessup, J. M., and Steele, G. D., Jr. Characterization of the tumorigenic and metastatic potential of a poorly differentiated human colon cancer cell line. Inv. Metastasis, 10: 253-266, 1990.
34. Giavazzi, R., Jessup, J. M., Campbell, D. E., Walker, S. M., and Fidler, I. J. Experimental nude mouse model of human colorectal cancer liver metastases. J. Natl. Cancer Inst., 77: 1303-1308, 1986.
35. Giavazzi, R., Campbell, D. E., Jessup, J. M., Cleary, K., and Fidler, I. J. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res., 46: 1928-1933, 1986.
36. Tibbetts, L. M., Doremus, C. M., Tzanakakis, G. N., and Vezeridis, M. P. Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production. Cancer (Phila.), 71: 315-321, 1993.
37. Behr, T. M., Sgouros, G., Stabin, M. G., Béhé, M., Angerstein, C., Blumenthal, R. D., Apostolidis, C., Molinet, R., Sharkey, R. M., Koch, L., Goldenberg, D. M., and Becker, W. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin. Cancer Res., 10 (Suppl.): 3031s-3043s, 1999.
38. Behr, T. M., Wulst, E., Radetzky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-Fränk, M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57: 5309-5319, 1997.
39. Sharkey, R. M., Filion, D., Fand I., Primus, F. J., and Goldenberg, D. M. A human colon cancer metastasis model for radioimmunodetection. Cancer Res., 46: 3677-3683, 1986.
40. Sharkey, R. M., Weadock, K. S., Natale, A., Haywood, L., Aninipot, R., Blumenthal, R. D., and Goldenberg, D. M. Successful radioimmunotherapy for lung metastasis of human colonie cancer in nude mice. J. Natl. Cancer Inst., 83: 627-632, 1991.
41. 131I-labeled monoclonal antibodies. Cancer Res., 52: 6036-6044, 1992.
42. Dunn, R. M., Juweid, M., Sharkey, R. M., Behr, T. M., and Goldenberg, D. M. Can occult metastases be treated by radioimmunotherapy? Cancer (Phila.), 80: 2656-2659, 1997.
43. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res., 57: 2181-2186, 1997.